Media Articles Related to Protriptyline
Exercise protects against depression - but how?
Source: Anxiety / Stress News From Medical News Today [2014.09.26]
Although previous research has shown that exercise can be beneficial for people who are depressed, the mechanism behind this benefit has not been clear. A new study investigates.
Nature Walks With Others May Keep Depression at Bay
Source: MedicineNet Depression Specialty [2014.09.26]
Title: Nature Walks With Others May Keep Depression at Bay
Category: Health News
Created: 9/25/2014 6:36:00 PM
Last Editorial Review: 9/26/2014 12:00:00 AM
Complicated Grief Treatment Trumps Depression Therapy
Source: Medscape Psychiatry & Mental Health Headlines [2014.09.25]
An intervention specifically targeting complicated grief is superior for improving symptoms in older adults than interpersonal psychotherapy, commonly used to treat depression, a randomized trial shows.
Medscape Medical News
Unique interaction discovered between brain regions involved in addiction and depression
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2014.09.24]
NIDA IRP researchers have discovered a unique interaction between a nerve cell in the brain's ventral tegmental area and the lateral habenula - a pathway implicated in mental health disorders such...
Ketamine: The Future of Depression Treatment?
Source: MedicineNet Depression Specialty [2014.09.24]
Title: Ketamine: The Future of Depression Treatment?
Category: Health News
Created: 9/24/2014 11:00:00 AM
Last Editorial Review: 9/24/2014 12:00:00 AM
Published Studies Related to Protriptyline
Effect of protriptyline, 10 mg daily, on chronic hypoxaemia in chronic obstructive pulmonary disease. [1995.03]
A daily dose of 20 mg of protriptyline can improve daytime arterial blood gas tensions in chronic obstructive pulmonary disease (COPD)... Despite the low dose, anticholinergic side-effects occurred in most patients.
The use of protriptyline for respiratory failure in patients with chronic airflow limitation. [1990.07]
Treatment of nocturnal hypoventilation in patients with restrictive chest wall disease and respiratory failure, results in improved daytime arterial blood gas tensions, increase in functional ability and longer survival. Success has been achieved with the use of protriptyline which reduces the duration of rapid eye movement (REM) sleep during which nocturnal hypoventilation occurs.
Effect of protriptyline on ventilatory responses to hypercapnia and asphyxia in normal subjects. [1989.09]
A double-blind crossover study was undertaken to assess the effect of protriptyline on ventilatory responses in normal subjects. Seven subjects received in random order placebo, 10 mg and 20 mg protriptyline daily for 2 weeks... Mean HCVR and HVR following 10 mg and 20 mg protriptyline did not differ significantly from measurements on placebo, neither for the single dose study or after 2 weeks.
Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome. [1988.10]
The role of drug therapy in the treatment of the sleep apnea/hypopnea syndrome is unclear. In a randomised, double-blind, placebo-controlled study, we investigated the value of 14-day therapy with protriptyline (20 mg daily) or acetazolamide (250 mg 4 times per day) on symptoms and on the frequency of apneas, hypopneas, arousals, and 4% desaturations in 10 patients with obstructive sleep apnea/hypopnea syndrome.
Clinical Trials Related to Protriptyline
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism [Recruiting]
Reduction of volume of the hippocampus has been associated with major depression in many
studies. It has been suggested that antidepressants may protect against hippocampus volume
loss in humans associated with multiple episodes of depression and may also reverse the
reduction of volume caused by the depression. In addition, genetic markers for serotonin are
implicated with depression, and may be an indication of reduced response to antidepressant
This study aims to enroll patients who are defined as having treatment resistant depression
(no remission after at least 2 treatments trials with an antidepressant). They will receive
an MRI scan at the initial visit and either 6 months after sustained remission or 12 months
after they enter the study for non-remitters. They will also be asked to give a blood sample
for genotyping. They will be matched by age and handedness to healthy volunteers with no
personal history of depression who will also receive an MRI scan and genotyping.
The first aim is to compare hippocampal volume of depressed subjects to healthy controls. It
is anticipated that subjects will initially have smaller hippocampal volume but of those who
sustain remission, there will be a small increase in hippocampal volume. It is also
anticipated that specific genetic markers will be related to individuals response to